DDMAC warns Allergan, Galderma Labs on promo materials

Share this article:
The Division of Drug Marketing and Communications (DDMAC) warned Allergan about a journal ad for Aczone, and Galderma Laboratories about two professional visual aids for Tri-Luma Cream.

In a letter dated August 18, DDMAC told Allergan that a journal ad (here, in pdf) for Aczone, a topical acne medication, was false or misleading because of an overstated efficacy and the omission of material facts and risk information. In the letter, DDMAC singled out a claim made in the advertisement – that Aczone “works fast – 24% reduction in inflammatory lesions at 2 weeks" – calling the statement “a complete misrepresentation of the results of the Draelos study.”

The letter goes on to describe a “grossly” overstated efficacy in the ad, which presents only the most favorable result for Aczone and ignores the placebo response. Additionally, the ad failed to include drug interaction information about Aczone, related to “temporary local yellow or orange discoloration of the skin and facial hair,” according to the letter. Cathy Taylor, a spokesperson for Allergan, confirmed that the violative ad ran in journals during the months of March, April and May, but has not been used since. Taylor declined to name which agency worked on the ads.  

Another DDMAC warning letter sent to Galderma Laboratories and dated August 18 took issue with two professional visual aids (here, in pdf) for Tri-Luma cream, a short-term treatment for facial melasma, or skin discoloration. The visual aids were considered violative based on recommended or suggested uses for Tri-Luma that were not FDA-approved, unsubstantiated claims that overstated the efficacy of the product, and dissemination of the visual aids with an unapproved version of the product labeling.

“These violations are extremely concerning from a public health perspective because they suggest that Tri-Luma is useful in a much broader range of patients and conditions than has been demonstrated by substantial evidence or substantial clinical experience, and that it is safer and more effective than has been demonstrated [by same]”, DDMAC admonished in the letter.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...